Kubota Pharmaceutical Holdings Co., Ltd.
4596窪田製薬ホールディングス株式会社
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-14For the first half of the fiscal year to 2026-12: Revenue ¥0 billion (-39.8% YoY), Profit before tax ¥-0.6 billion, Net income ¥-0.6 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥8m | -39.8% |
| Profit before tax | −¥649m | — |
| Net profit to owners | −¥649m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4596/earnings-releases.
Financials
IFRS · consolidated · fiscal year to 2025-12-31- Revenue
- ¥21m
- Net income
- −¥676m
- ROE
- -42.2%
- Equity ratio
- 91.6%
- Dividend / share
- —
- Employees
- 8
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥21m | −¥676m | ¥1,979m | ¥1,814m | -42.2% | ¥-10.59 | −¥583m |
| 2024-12-31 | ¥27m | −¥1,333m | ¥1,542m | ¥1,390m | -66.0% | ¥-23.65 | −¥1,195m |
| 2023-12-31 | ¥40m | −¥1,490m | ¥3,017m | ¥2,647m | -45.2% | ¥-26.79 | −¥1,336m |
| 2022-12-31 | ¥8m | −¥2,016m | ¥4,420m | ¥3,950m | -49.8% | ¥-40.92 | −¥2,087m |
| 2021-12-31 | — | −¥2,616m | ¥4,833m | ¥4,153m | -51.6% | ¥-57.46 | −¥2,514m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | -42.2 | 1.1 |
| Ordinary margin | -31.6969 | 0.1 |
| Equity ratio, % | 91.6 | 99 |
| Revenue growth | -0.2153 | 2.4 |
| Net income growth | 0.4926 | 74.7 |
| Operating cash flow / assets | -0.2945 | 1.7 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Via /v1/companies/4596/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themOwnership changes
All companies →- 2026-07-14
Evo Fund cut holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 4.32% from 8.19%, below the 5% threshold.
- 2026-07-08
Evo Fund raised holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 8.19% from 6.18%.
- 2026-07-06
Evo Fund reduced holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 6.18% from 8.37%.
- 2026-07-06
Evo Fund filed a correction to a 5% report on Kubota Pharmaceutical Holdings Co., Ltd. (4596).
- 2026-07-02
Evo Fund reduced holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 8.37% from 8.73%.
- 2026-06-23
Evo Fund reduced holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 8.73% from 9.73%.
- 2026-06-10
Evo Fund reduced holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 9.73% from 10.83%.
- 2026-06-10
Holdings of Evo Fund in Kubota Pharmaceutical Holdings Co., Ltd. (4596) moved below 10% (10.83% -> 9.73%).
- 2026-06-01
Evo Fund reduced holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 10.83% from 11.87%.
- 2026-05-18
Evo Fund raised holdings in Kubota Pharmaceutical Holdings Co., Ltd. (4596) to 11.87% from 11.62%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Evo Fund | 2025-12-18 – 2026-07-07 | +3,531,000 | +2.29pt | ¥171.74 | ¥53–238 |
| Evolution Capital Management LLC | 2025-12-18 – 2026-07-07 | +3,531,000 | +2.29pt | ¥171.74 | ¥53–238 |
| individual filer | 2019-09-27 – 2025-12-22 | +36,639,300 | +32.46pt | ¥7 | ¥7–7 |
| individual filer | 2025-12-22 – 2025-12-22 | +14,285,700 | +12.38pt | ¥7 | ¥7–7 |
| Barclays Capital Securities Ltd. | 2021-11-24 – 2025-09-02 | -562,700 | −0.75pt | ¥152.57 | ¥40–301 |
| Barclays Bank PLC | 2022-06-14 – 2025-09-02 | +5,409,900 | +6.67pt | ¥183.73 | ¥124–231 |
| バークレイズ証券株式会社 | 2021-11-24 – 2025-08-04 | 0 | 0.00pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4596/trades.
5% filings
Large shareholding reports on 4596| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-07-14 | Evo Fund | 4.32% | −3.87pt | pure investment |
| 2026-07-08 | Evo Fund | 8.19% | +2.01pt | pure investment |
| 2026-07-06 | Evo Fund | 6.18% | −2.19pt | pure investment |
| 2026-07-06 | Evo Fund | 8.37% | −0.36pt | pure investment |
| 2026-07-02 | Evo Fund | 8.37% | −0.36pt | pure investment |
| 2026-06-23 | Evo Fund | 8.73% | −1.00pt | pure investment |
| 2026-06-10 | Evo Fund | 9.73% | −1.10pt | pure investment |
| 2026-06-01 | Evo Fund | 10.83% | −1.04pt | pure investment |
| 2026-05-18 | Evo Fund | 11.87% | +0.25pt | pure investment |
| 2026-05-01 | Evo Fund | 11.62% | −0.82pt | pure investment |
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| individual holder | 40,974,000 | 35.51% |
| 窪田アセットマネージメント株式会社 | 14,285,000 | 12.38% |
| 株式会社ＳＢＩ証券 | 1,175,000 | 1.02% |
| さくらＧＳ株式会社 | 500,000 | 0.43% |
| 大和証券株式会社 | 352,000 | 0.31% |
| individual holder | 350,000 | 0.30% |
| individual holder | 341,000 | 0.30% |
| individual holder | 306,000 | 0.27% |
| individual holder | 238,000 | 0.21% |
| individual holder | 231,000 | 0.20% |
Get this as JSON
GET /v1/companies/4596
GET /v1/companies/4596/financials
GET /v1/companies/4596/details
GET /v1/companies/4596/segments
GET /v1/companies/4596/voting
GET /v1/companies/4596/tender-offers
GET /v1/companies/4596/indicators
GET /v1/companies/4596/earnings-releases
GET /v1/events?ticker=4596
GET /v1/companies/4596/trades
GET /v1/companies/4596/cross-holdings
GET /v1/companies/4596/brief